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Summary statement: We have determined the crystal structure of Gremlin-1 and analyzed its interaction 
with BMP-2. Our results suggest that Gremlin-1 does not inhibit BMP-2 by direct 1:1 binding, but 
possibly has a novel mechanism of sequestering BMP-2 into a larger oligomeric complex.  
ABSTRACT 
Bone morphogenetic protein 2 (BMP-2) is a member of the transforming growth factor-β (TGF-β) 
signaling family and has a very broad biological role in development. Its signaling is regulated by many 
effectors: transmembrane proteins, membrane attached proteins and soluble secreted antagonists such as 
Gremlin-1. Very little is known about the molecular mechanism by which Gremlin-1 and other DAN 
family proteins inhibit BMP signaling. We analyzed the interaction of Gremlin-1 with BMP-2 using a 
range of biophysical techniques, and used mutagenesis to map the binding site on BMP-2. We have also 
determined the crystal structure of Gremlin-1, revealing a similar conserved dimeric structure as has been 
seen in other DAN family inhibitors. Measurements using biolayer interferometry indicate that Gremlin-1 
and BMP-2 can form larger complexes, beyond the expected 1:1 stoichiometry of dimers, forming 
oligomers that assemble in alternating fashion. These results suggest that inhibition of BMP-2 by 
Gremlin-1 occurs by a mechanism that is distinct from other known inhibitors such as Noggin and 
Chordin and we propose a novel model of BMP-2/Gremlin-1 interaction yet not seen among any BMP 
antagonists, and cannot rule out that several different oligomeric states could be found, depending on the 





Gremlin-1 is an extracellular antagonist of the bone morphogenetic proteins (BMPs) and functions by 
directly neutralizing its ligands and inhibiting BMP signaling [1–4]. BMPs, together with their 
antagonists, are responsible for regulating many important processes during early embryonic development 
[5–11], and have broad and complex biological roles [3,12–14]. Signal propagation by BMPs is initiated 
when a dimer of the mature BMP binds to two types of serine-threonine kinase receptors, a specific high-
affinity type I receptor and a lower affinity type II receptor. With only seven type I and five type II 
receptors for over thirty TGFβ-like ligands in humans, several ligands can interact with any particular 
receptor but at the same time one ligand can interact with several type I and type II receptors [15–17]. 
This results in high complexity of signaling and also raises the question as to how BMPs can exert so 
many cellular functions and highlights the need for another level of signaling modulators that could  
attenuate the levels of active BMP [18,19]. In the case of  BMPs one of the key mechanisms of signal 
regulation is via the interaction with secreted antagonists such as noggin, chordin [3,20] and Gremlin-1, 
which can specifically bind to BMPs and prevent their interaction with receptors [21]. 
Gremlin-1 belongs to the DAN family of secreted BMP antagonists. The this family, named after the 
prototypical member  Dan (differential screening-selected gene aberrative in neuroblastoma), contains 
also proteins Cerberus, Gremlin-1, Gremlin-2 (also called as Protein related to Dan and Cerberus, PRDC), 
Coco, Sclerostin and uterine sensitization-associated gene-1 (USAG-1) [1–4]. BMP antagonists have 
many roles in development and are also implicated in many disorders [6]. In lungs Gremlin-1 
overexpression inhibits BMP-7 resulting in myofibroblast apoptosis and fibrotic response, while in 
hepatic stellate cells increase in Gremlin-1 expression contributes to liver failure [4,22–24]. Gremlin-1 is 
also expressed at the base of intestinal crypts, helping to maintain the stem cell pool by countering the 
BMP activity that arises from the mesenchymal cells [25]. Overexpression of Gremlin-1 has also been 
shown in stromal cells in tumors, where it helps to create a favorable niche for the cancer cells to grow in 
[26,27].  
The first DAN family protein to have its three-dimensional structure determined was Sclerostin [28,29].  
The solution NMR structure of Sclerostin revealed a monomeric protein containing a cystine knot core 
and an elongated shape comprising two -stranded fingers on one side of the central cystine knot and 
three flexible loops on the opposite side. Very recently, the crystal structures of Gremlin-2 and Dan have 
also been determined [30,31]. The structure of Gremlin-2 revealed a non-covalent dimer that forms 
through extensive hydrogen bonding between the β-sheets of its two protomers [31]. Dan shares a similar 
architecture, with an identical mode of non-covalent dimerization [32]. To date, no structures of DAN 
family proteins in complex with BMPs have been published and it remains unclear how they inhibit BMP 
signaling at molecular level. Do these antagonists act by blocking one or both receptor binding sites, as 
has been shown to be the case for Noggin and Crossveinless-2 [20,33], or do they reveal a different mode 
of inhibition altogether? Dan-like proteins are structurally distinct from other BMP inhibitors, and the 
structures of Dan, Gremlin-2 and Sclerostin have so far provided few clues about the molecular 
mechanism and specificity of inhibition.  
To broaden our understanding of DAN family BMP antagonism, we have studied the mechanism of BMP 
inhibition by Gremlin-1 and determined its crystal structure. Analytical ultracentrifugation (AUC), 
dynamic light scattering (DLS) and analyses of the interaction between BMP-2 mutants and Gremlin-1 
have been used to delineate the molecular details of the binding mechanism. Based on our findings, we 





Protein expression, refolding and purification 
Constructs of Gremlin-1 (UniProt #O60565) were amplified by PCR using human Gremlin-1 cDNA as 
template (kind gift from Dr Katri Koli, University of Helsinki) with primers listed in the Supplementary 
Table 1. The fragments encoding full-length construct (fl-Gremlin-1, residues 25 – 184, lacking only its 
signal sequence) and a shorter one (ΔN-Gremlin-1, residues 72 – 184) were cloned as BspHI-HindIII 
fragments into pHAT4 and pBAT4 vectors and confirmed by sequencing. The pHAT4 constructs contain 
an N-terminal hexa-His-tag with TEV protease cleavage site, whereas the pBAT4 constructs are 
untagged.  A synthetic E. coli codon-optimized gene encoding mature BMP-2  was cloned into pBAT4 
vector [34]. PCR based site-directed mutagenesis was used to introduce desired BMP-2 mutations. All 
proteins were expressed in E. coli strain BL21(DE3), which in the case of  Gremlin-1 expression was also 
carrying  plasmid pUBS520 to compensate for codon usage differences [35]. Bacteria were grown in 
2xYT medium at 37°C until the OD600 reached 0.8-1.0, after which expression was induced by addition 
of 400 uM IPTG and continued for three hours. Pelleted cells were resuspended in water and stored at -
20°C.  
All constructs of Gremlin-1, as well as BMP-2 and mutant variants were expressed insolubly and 
subsequently refolded to active form. Gremlin-1 inclusion bodies were solubilized in 6 M GndHCl, 25 
mM TCEP, 50 mM Tris pH 8.0, 0.5 mM EDTA and refolded by rapid dilution into refolding buffer 
containing 1 M PPS, 50 mM Tris pH 8.0, 50 mM ethylendiamine, 2 mM EDTA, 2 mM cysteine, 0.2 mM 
cystine and left for 7 days at 4°C. Gremlin-1 was purified by ion-exchange chromatography using HiTrap 
SP HP 5 ml column (GE Healthcare) equilibrated with 20 mM Hepes, pH 7.0. Filtered refolding solution 
was loaded directly onto the column, washed with the equilibration buffer and bound proteins were eluted 
using a linear gradient to 1 M NaCl. Pooled fractions from the ion exchange were acidified and purified 
further by reverse phase chromatography (RPC) using ACE 5 C8-300 column (Hichrom Ltd) that was 
equilibrated with 10% acetonitrile (ACN), 0.1% trifluoroacetic acid (TFA). Bound protein was eluted 
using a linear 20% to 40% gradient in 10 column volumes, with 90% ACN, 0.1% TFA.  
For the refolding of BMP-2 and its mutants, the inclusion bodies were solubilized using 10 mM TCEP, 6 
M GndHCl, 0.5 mM EDTA, 50 mM Tris pH 8.0 and refolded in 1 M PPS, 100 mM Tris pH 8.0, 100 mM 
ethylendiamine, 300 mM NaCl, 0.5 mM EDTA, 2 mM cysteine, 0.2 mM cystine. Solubilized inclusion 
bodies were added to the refolding buffer in small aliquots with 6 days in between and kept at 4°C for up 
to 2 weeks to allow disulfide exchange. BMP-2 variants were purified by RPC using 10 ml Source RPC 
15 (GE Healthcare) column by loading refolded material directly onto the column and eluting bound 
proteins using a linear gradient of  10% to 45% acetonitrile  (with 0.1% TFA) in 13 column volumes. All 
protein concentrations were determined by absorbance at 280 nm using calculated molecular extinction 








 for BMP-2s. BMP-2 
and its mutants were lyophilized after purification by reverse phase chromatography and re-suspended to 
protein concentration of 0.15 mg/ml in MilliQ water. Circular dichroism (CD) spectrum at 189-250 nm 
was measured for each of the proteins three times. Each scan was baseline corrected, the three 
measurements averaged and smoothened to produce the final CD spectra. Secondary structure content 
was estimated using K2D3 server at http://cbdm-01.zdv.uni-mainz.de/~andrade/k2d3/.   
Multi-angle light scattering (MALS) experiments were carried with a DAWN HELEOS 8 detector with a 
wavelength of 664 nm and Optilab T-rEX refractometer (Wyatt Technology,). MALS analysis was 
performed using a Superdex 200 Increase 10/300 (GE Healthcare) column equilibrated with PBS (137 
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mM NaCl, 3 mM KCl, 8 mM Na2HPO4, 15 mM KH2PO4) containing an additional  0.4 M NaCl, 0.5 M L-
Arg and 5% glycerol, pH 8.0. All the samples were loaded onto the column at concentration of 1 mg/ml. 
Data was analyzed with ASTRA software (Wyatt Technology) and molecular weight was calculated 
using Debye fit model.  
Interaction and bioactivity assays 
Biolayer interferometry (BLI) using an Octet RED96 (PallGelman/ForteBio) instrument was used for the 
analysis of BMP-2/Gremlin-1 interactions. All experiments were performed using anti-penta-His antibody 
biosensors (PallGelman/ForteBio), which were regenerated at most eight times with 10 mM glycine pH 
1.7. All samples were prepared in kinetics buffer (1 PBS, pH 7.4, 0.01% BSA, and 0.002% Tween-20, 
400 mM NaCl, 0.02% P20).  A schematic diagram of the experimental setup is shown in Supplementary 
Table 2. Data was processed using ForteBio Data Analysis 7.1 software and fit using Origin Pro 9.0 
package.  
BMP-2 bioactivity assays were completed using C2C12 mouse myoblasts which can be induced to 
secrete alkaline phosphatase by BMP-2 [36]. C2C12 cells at passages 5–10 were subcultured in DMEM 
containing 10% FBS at 37°C in a humidified atmosphere of 5% CO2 in air. For alkaline phosphatase (AP) 
assay, cells were diluted to 5000 cells/ml and aliquoted into 96-well plates. Plates were treated with BMP-
2 and Gremlin-1 the following day. Serial dilutions of proteins were performed in sterile DMEM. After 
48 hours the cells were washed with PBS and lysed by addition of 0.56 M 2-amino-2-methyl-propan-1-ol 
and 0.1% SDS pH 10.0. AP activity was measured by adding the substrate pNPP, which develops a 
soluble yellow reaction product, and absorbance read at 405 nm using BMG PHERAstar FS plate reader. 
All C2C12 experiments were repeated six times. Data was analyzed using Origin Pro 9.0 software. 
Structural studies  
His-tagged ΔN-Gremlin-1 was used for crystallization at 8 mg/ml concentration in 20 mM Hepes pH 8.0. 
Crystals formed in 2.1 M NaCl, 0.1 M sodium acetate pH 4.5, 0.3 M LiSO4. For data collection, the 
crystals were cryo-cooled in liquid N2 in the crystallization solution containing 30% ethylene glycol as a 
cryoprotectant. Data was collected at beamline I04 at the Diamond Light Source. Collected data was 
integrated and analyzed using autoPROC software package [37]. The phases were found by molecular 
replacement with the structure of Gremlin-2 (PDB code: 4JPH) using Amore package in the CCP4 suite 
[38]. The model was manually corrected using Coot 0.8.1 [39] and refined with Refmac5 [38]. The 
coordinates and structure factors have been deposited in the Protein Data Bank under accession number 
5AEJ. 
Samples for small-angle X-ray scattering (SAXS) were measured at 1 mg/ml concentrations in PBS 
buffer with 0.4 M NaCl, 0.5 M L-Arg and 5% glycerol using Superdex 200 3.2/300 Increase size 
exclusion column (GE Healthcare) with inline data collection chromatography run . Data was collected at 
beamline I22 at the Diamond Light Source. Data processing and analysis was performed using Scatter and 
ATSAS suite software [40].  
Analytical ultracentrifugation 
Analytical ultracentrifugation (AUC) analyses were performed using Beckman Optima XL-I instrument 
using both UV and interference optics. ΔN-Gremlin-1, BMP-2 and mixture of both proteins were dialyzed 
overnight against reference buffer (100 mM sodium acetate pH 5.0) before centrifugation and used at 






Gremlin-1 interaction with BMP-2 and functional activity assays  
DAN protein family members are typically composed of 180-270 amino acid residues (excluding signal 
peptide). Overall sequence identity between any two DAN proteins tends to be relatively low, 10-30 %, 
increasing by some 10 % if we consider the C-terminal cystine knot domain only (alignment of human 
DAN family proteins are shown in supplementary Figure S1). Two pairs of Dan family members share 
higher than average pairwise sequence identity in their cysteine-rich domains: Gremlins 1 and 2 (65 %) 
and Sclerostin and USAG-1 (45%). The N-terminal parts of the proteins, outside the cystine knot 
domains, differ greatly both in sequence and in length. It is not clear what the role of the N-terminus is, 
but it is possibly important in determining binding specificity, localization or maybe involved in 
mediating interactions with other proteins [2]. Well characterized inhibitor BMP-2 Noggin mediates its 
interaction largely with its N-terminal segment that is not part of the structured cystine knot domain, 
raising possibility that DAN proteins function in a similar manner [20].   
We have created two constructs of Gremlin-1: a full-length construct (fl-Gremlin-1), comprising the 
residues 25 – 184 (lacking only the signal peptide) and a shorter one, ΔN-Gremlin-1, comprising residues 
72 – 184, lacking the entire variable N-terminal sequence. This allowed us to investigate the possible role 
of the N-terminal part of Gremlin-1 in mediating the interaction with BMP-2 and its effect on the 
inhibition of BMP-2 signaling in mouse myoblasts.  
The SDS-PAGE gel in Figure 1A shows the purity of all constructs of Gremlin-1 after the final reverse 
phase chromatography step, with the arrowheads indicating positions of the monomeric Gremlin-1 
proteins. On a non-reducing SDS-PAGE gel Gremlin-1 runs as a characteristic tailed band and some 
higher oligomeric species are visible while a reducing gel shows one sharp main band with a small 
proportion of low molecular weight contaminants.  
Firstly, Gremlin-1 interaction with BMP-2 was analyzed using biolayer interferometry (BLI). We 
immobilized His-tagged fl-Gremlin-1 or ΔN-Gremlin-1 on the biosensors using anti-penta-His antibody 
and measured their interaction with BMP-2 in solution (Figure 1B and S2). Measured binding affinities 
for both constructs with BMP-2 are in close agreement, with Kd values of 5.6 nM and 5.2 nM for fl-
Gremlin-1 and ΔN-Gremlin-1, respectively, when data was fit using steady state equilibrium model, and 
9.0 nM and 16.7 nM  when estimated from kinetic data. The dissociation constant of the BMP-2/Gremlin-
1 complex has been previously reported as 32 nM using surface plasmon resonance, which is in good 
agreement with our values [42]. 
We then analyzed the ability of both full length and truncated Gremlin-1 to inhibit BMP-2 signaling in 
C2C12 mouse myoblast cells. BMP-2 induces the differentiation of C2C12 cells into osteoblasts, with an 
associated increase in secretion of alkaline phosphatase which can be readily analyzed using a 
colorimetric enzyme assay [36]. To determine the half maximal effective concentration (EC50) and select 
an optimal dose of BMP-2 for studying the inhibitory effect of Gremlin-1, C2C12 cells were first treated 
with BMP-2 alone. We measured an EC50 value of 52 nM using this assay, comparable to published 
values for recombinant BMP-2 [43,44]. In order to measure the inhibitory effect of Gremlin-1, C2C12 
cells were treated with 150 nM concentration of BMP-2 (corresponding to over 90% activation of the 
cells) and varying concentrations of fl-Gremlin-1 or ΔN-Gremlin-1. Both forms of Gremlin-1 were shown 
to be active and were able to inhibit BMP-2 induced myoblast differentiation with half maximal 
inhibitory concentrations (IC50) of 130 nM for fl-Gremlin-1 and 230 nM for ΔN-Gremlin-1 (Figure 1C). 
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In contrast to the affinity measurements of the direct interaction in vitro where both proteins were equally 
potent in binding to BMP-2, the full length protein had approximately 2-fold higher IC50 in this cellular 
assay. This modest, but reproducible difference in inhibition suggests that the N-terminal ‘clip’ region 
could play a role in the bioactivity of Gremlin-1, possibly by localizing the protein in the extracellular 
environment and thus facilitating binding to its ligand. The longer construct has a net charge increase of 
+4 compared to the shorter construct  and almost a unit higher calculated isoelectric point (9.96 vs 9.17), 
possibly contributing to increased affinity towards heparan sulfates, to which both Gremlin-1 and BMP-2 
are known to bind [45,46]. 
Crystal structure of ΔN-Gremlin-1  
Given that the N-terminal sequence of Gremlin-1 does not appear to be important for direct interaction 
with BMP-2, we focused our structure determination efforts on ΔN-Gremlin-1 construct.  This protein 
crystallized readily and we have determined its structure at 1.9 Å resolution (Table 1). The structure was 
solved by molecular replacement using the structure of Gremlin-2/PRDC as the search model (PDB code: 
4JPH) [31] yielding clearly interpretable electron density for all of the construct  and refined to a final 
model with good final stereochemistry and refinement statistics (Table 1 and Figure S3A). 
As has been seen with Gremlin-2, Gremlin-1 is a non-covalently linked dimer with overall dimensions of 
100 Å × 37 Å × 30 Å (Figure 2A). The overall shape of the Gremlin-1 dimer resembles a bent rod and 
exposes large convex and concave surfaces (Figures 2B and C). The protomer is composed of intertwined 
antiparallel β-strands with a typical cystine knot core consisting of six cysteine residues. The structure can 
be described as a composition of two fingers (F1, F2) and a wrist (W) (Figure 2A). An additional 
disulfide bond is found in the finger region crosslinking the two fingers. Gremlins, Dan and Sclerostin all 
share the same arched shape of the protomer (Figure S4). 
These Gremlin-1 crystals contain two dimers in the asymmetric unit (ASU). The two dimers align very 
well, and show significant differences only in the finger region, partly driven by crystal contacts (Figure 
S3B). Analysis of the B-factors of all chains in the ASU highlights the structural flexibility within the 
dimers, with the finger loops showing highest B-factors, whereas the cores of the dimers are relatively 
rigid (Figure S3C). 
The dimerization mode is very similar to other known Dan family members (Gremlin-2 and Dan 
structures are compared with Gremlin-1 in Figure S4A and C) with the continuous β-sheets with 
extensive hydrogen bonding between protomers stabilizing the dimer and  producing a ‘head to tail’ 
structure (Figure 2B).  The interactions responsible for strong dimer formation are backbone hydrogen 
bonds between residues F117 to I127. This interface constitutes eight hydrogen bonds and composes 
more than half of the interacting surface. Additionally, more than 30 hydrophobic contacts were identified 
between Gremlin-1 protomers using LigPlot software [47].  In total,  surface area of  approximately 1900 
Å
2
 per protomer is buried upon dimerization, similar to that of Gremlin-2 (≈1800 Å2) [31] (Figure 2C). 
 In the N-terminus an -helix links the interfaces of the protomers. The -helix plays important role in the 
interacting surface as well and has intimate contacts with hydrophobic residues of both chains over the 
shared-sheet (Figure 2D). The interacting interface is formed by residues F125, I127, F138 from one 
protomer and W93, L99, F117 from the other, with Y88 from the -helix hydrogen bonding with Q97 of 
the other protomer. These residues place the helix on top of the convex surface and provide additional 
interactions between the protomers. For Gremlin-2, this -helix has high temperature factors and the 
authors propose that it does not contribute to the dimer formation. The B-factors in Gremlin-1 -helices 
are similar to the rest of the structure (Figure S3C) suggesting it is less mobile than in Gremlin-2 and thus 
likely to contribute to the stabilization of the dimeric structure. 
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One non-disulfide bonded cysteine (C141) is found close to the dimer interface. In TGF--family growth 
factors a similarly positioned cysteine forms a disulfide bridge with another protomer and is responsible 
for covalent dimerization. In the structure of Gremlin-1 however, C141 does not form a interchain 
disulfide bridge, despite the close proximity (4.2 Å) of the two sulfhydryl groups (Figure 2E and S3A). 
The side chains of  F143 flank the cysteines from the each protomer and appear to prevent the formation 
of  a disulfide bridge, as is suggested for Gremlin-2 [31]. Dan protein has an additional cysteine which 
forms an intra-chain disulfide bond with cysteine equivalent to C141 in Gremlin-1 [30]. It is intriguing 
that such conserved cysteines are found in close proximity and exposed to solvent. One can speculate that 
these free cysteines could form disulfides, either within Gremlin-1 dimer or with another molecule, as 
part of Gremlin’s function in the extracellular matrix.    
MALS and SAXS analysis of Gremlin-1  
In order to verify that the non-covalent dimeric structure observed in the Gremlin-1 crystals is 
representative of the solution structure, we used two different solution based methods to confirm this. 
Firstly, multi-angle light scattering (MALS) analysis was performed on His-tagged ΔN-Gremlin-1 to 
determine its molecular mass in solution. The protein elutes in a single peak from a size exclusion column 
and MALS analysis shows that the protein molecular mass of 34.7 kDa, in very good agreement with the 
predicted mass of 35.0 kDa for dimeric ΔN-Gremlin-1 (Figure 3A).  
Small-angle X-ray scattering (SAXS) analysis was used to validate the overall structure of fl-Gremlin-1 
and ΔN-Gremlin-1 in solution. SAXS data was obtained at Diamond synchrotron using an inline data 
collection system during size-exclusion chromatography run. The linearity of the Guinier plot in the low q 
region indicate that protein preparations are monodisperse and free of aggregation (Figure S5A). Also, the 
calculated radius of gyration (Rg) values from both reciprocal and real space were highly similar: for ΔN-
Gremlin-1 Rg(Rec) = 30.23, Rg(Real) = 30.26, while for fl-Gremlin-1 Rg(Rec) = 31.54, Rg(Real) = 31.64. 
The pair-distance distribution functions P(r) indicate that both long and short constructs of Gremlin-1 
have an elongated form with a maximal radius (Dmax) of 100Å (Figure S5B). The experimental small-
angle X-ray scattering curves of ΔN-Gremlin-1 and fl-Gremlin-1 as well as simulated curves derived 
from our crystal structure of the ΔN-Gremlin-1 are in close agreement (Figure S5C) with lower chi (χ) 
score for the dimeric structure compared to isolated monomer both for  Fl-Gremlin-1  (5.628 for dimer vs. 
7.752 for monomer) and for ΔN-Gremlin-1 (1.722 vs.4.261).  This difference is most likely due to 
additional 47 residues in the N-terminus of fl-Gremlin-1, resulting in a poorer fit against the ΔN-Gremlin-
1 crystal structure which lacks these residues. Three-dimensional dummy atom models (DAMs) of both 
constructs were generated from the SAXS curves. Low resolution envelopes were first generated ab initio 
and aligned with crystal structure of ΔN-Gremlin-1 (Figure 3B and C). From SAXS analysis and overlaid 
models it is clear that the overall shape of both constructs of Gremlin-1 in solution are consistent with the 
dimeric structure seen in the crystal structure. It can also be observed that the envelope of fl-Gremlin-1 
occupies more space at the convex face of the protein, suggesting one possible position for the longer N-
terminal segment. 
Crystallographic analysis, MALS and SAXS all provide consistent results supporting the idea that 
Gremlin-1 exists as a stable dimer in solution. While the unique N-terminal portion does not play a key 
role in interaction with the growth factor ligand, it also does not significantly alter the overall shape of the 
domain.  
ΔN-Gremlin-1 interaction with BMP-2 mutants 
Previously reported mutational analysis of Gremlin-2 showed that mutations in the central convex surface 
of the protein reduced its ability to inhibit BMP signaling but still did not reveal the exact mechanism of 
inhibition [31]. In order to further probe the molecular determinants of the Gremlin-1: BMP-2 interaction, 
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we generated a number of BMP-2 mutants probing both type I and type II receptor binding sites. Based 
on analysis of BMP-2 quaternary complex with type I and II receptor ectodomain [5], we designed three 
type I receptor binding site mutants and four mutants with altered type II receptor binding site (Table 2, 
Figure S6). These seven BMP-2 mutants were expressed and purified for interaction analysis to determine 
which residues are responsible for Gremlin-1/BMP-2 complex formation. All mutants refolded efficiently 
and purified as disulfide linked dimers as expected. We analyzed their structure using CD spectroscopy, 
and while there are some differences, the predicted secondary structure content is relatively similar for all 
mutants (Figure S7A). Mutant 3 (a double mutant in type I receptor site) has the most differing CD 
spectrum, and predicted to have significantly reduced helical content. Since the two mutations in this 
mutant are interacting with each other, across the wrist epitope -helix, the reduced helical content is not 
entirely surprising. As is seen later, this mutant had similar effect to binding as other type I mutants, and 
hence the differing secondary structure does not appear to correlate with reduced binding properties of the 
protein. To validate the mutants biologically, the activity of each of the BMP-2 mutant was analyzed 
using the C2C12 cell differentiation assay. As expected from mutations affecting receptor binding site, all 
mutants were shown to be inactive or with greatly reduced activity compared to wild type protein (Figure 
S7B-C). Only mutant 2 (L66R) in type I receptor interaction site showed measurable activity, but even 
that was almost two orders of magnitude lower than the wild type BMP-2.  
We then used the same BLI binding assay to measure the affinity of each of the mutants for fl-Gremlin-1 
and ΔN-Gremlin-1 (Table 3 and Figure S8). These experiments show that Gremlin-1 can still interact 
with the BMP-2 mutants, albeit with lower binding affinities. BMP-2s with mutations in the type I 
receptor binding site had approximately 15-fold lower binding affinities than wild type BMP-2, whereas 
the type II receptor binding site mutants exhibited 30-60 fold reduction in affinity. This suggests that the 
residues in both BMP-2 receptor binding sites are involved in Gremlin-1 binding. Since Gremlin-1 and 
BMP-2 mutants still interact with one another, the idea that Gremlin-1 blocks only one of the receptor 
binding sites was not conclusively proven; no single mutant was able to abolished the binding completely, 
raising the question as to whether there could be an alternative mechanism by which BMP-2 signaling is 
inhibited.  
Biophysical analysis of BMP-2/ΔN-Gremlin-1 complex  
Analytical ultracentrifugation (AUC) was used to measure sedimentation velocity of ΔN-Gremlin-1, 
BMP-2 and complex samples in 50 mM acetate buffer pH 5.0, as dynamic light scattering (DLS) data 
showed the complex to be mostly monodisperse under these buffer conditions. Both AUC and DLS 
measurements gave similar information about the behavior of the protein. ΔN-Gremlin-1 has one sharp 
dimer peak with molecular weight of 37 kDa (calculated molecular weight is 35 kDa) with minor traces 
of monomeric and tetrameric species (Figure S9). BMP-2 has a broader and much less distinctive peak 
corresponding to a higher oligomeric form with minor traces of smaller particles. The molecular weight 
estimated from this data is approximately 380.0 kDa. With expected molecular weight of 26 kDa for a 
dimer, it appears that at pH 5.0 BMP- 2 forms aggregates. Interestingly, the complex sample contains 
smaller molecular weight particles than BMP-2 alone. The large broad peak has a maximum at 147 kDa 
and only minor traces of smaller species are visible (accordingly the molecular weight these may 
represent an excess of ΔN-Gremlin-1). The data suggest that Gremlin-1 and BMP-2 oligomerize, 
differently to the expected 1 BMP-2 dimer: 1 Gremlin-1 dimer complex which would have a molecular 
weight of 62 kDa. The data is not definitive and does not represent the real stoichiometry, but shows that 
Gremlin-1 at least partially reduces BMP-2 aggregation by sequestering it into a larger complex, possibly 
at stoichiometry close to 2:2 (Gremlin-1 dimers:BMP-2 dimers).  
The AUC data led to the hypothesis that Gremlin-1 and BMP-2 form large complexes. To study this 
further, we turned again to BLI analysis. While in a typical BLI experiment one measures first the 
association rate of the analyte to the immobilized binding partner followed by measurement of 
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dissociation rate in solution without the analyte, we decided to measure multiple association phases by 
alternating BMP-2 and Gremlin-1 as analytes. First, His-tagged ΔN-Gremlin-1 was immobilized on 
biosensors using anti-penta-His antibody. These sensors were then placed in wells containing different 
concentration of BMP-2 and association between the two proteins was recorded (as in previous 
experiments). Next, instead of measuring dissociation of the complex, the biosensors were moved directly 
into wells containing untagged ΔN-Gremlin-1 and association of Gremlin-1 to the sensors was monitored 
again. This sequence of incubating biosensor first in BMP-2 and then in untagged ΔN-Gremlin-1 was 
repeated once more (experimental set up is depicted in Figure 4A). BMP-2 was used at different 
concentrations (8-500 nM) while concentration of Gremlin-1 was kept constant at 500 nM to ensure 
saturation of binding in this step, allowing allowed us to fit the binding of the second BMP-2 molecule 
with a steady state model. Consecutive incubations of the biosensor in BMP-2 and in untagged ΔN-
Gremlin-1 resulted in continuous increase of the layer thickness on the biosensor tip, suggesting that 
untagged ΔN-Gremlin-1 bound to BMP-2 in an alternating manner. Steady state model fitting showed 
that the first and second BMP-2 binding events had very similar affinities with Kds of 5.2 nM and 8.5 nM, 
respectively. Appropriate control experiments without untagged Gremlin-1 in between BMP-2 
associations were also performed to ensure that the repeated binding is not due to non-specific interaction 
with the tips or BMP-2 or Gremlin-1 self-association (Figure 4B). 
Results of the additive BLI experiment indicate that Gremlin-1 can bind to more than one BMP-2 
molecule at the same time and vice versa. The Kd values of the first and the second binding of BMP-2 are 
in close agreement, suggesting that these are similar molecular events and supports the hypothesis that 
Gremlin-1 and BMP-2 form an oligomeric complex. The same repetitive binding analysis was performed 
with all BMP-2 mutants and showed the same increase in layer thickness with each binding step (data not 
shown). What is more, Kd values of the second binding of BMP-2 mutants were in close agreement with 
the binding affinities measured in the first His-tagged Gremlin-1 and BMP-2 interaction, demonstrating 
that mutations in the receptor binding sites of BMP-2 do not affect Gremlin-1 and BMP-2 
oligomerization.  
DISCUSSION  
During the course of this study binding and inhibition assays were performed with two Gremlin-1 
constructs, to assess the role of the unique N-terminal segment in BMP-2 binding. The N-terminal 
sequence of 47 amino acids had no noticeable effect on the binary Gremlin-1 and BMP-2 interaction, 
indicating that the N-terminus of Gremlin-1 does not directly participate in the interaction. This is in clear 
contrast to well characterized cysteine knot inhibitor Noggin, which interacts with BMP-2 using flexible 
N-terminal segments to cover both the type I and type II receptor binding sites [29]. In our cellular assay 
however, fl-Gremlin-1 was approximately twice as active as ΔN-Gremlin-1, indicating that the N-termini 
of Gremlin-1 dimer may be involved in mediating other interactions with the extracellular environment 
(eg. heparan sulfate binding), possibly co-localizing BMP-2 and Gremlin-1 and thus increasing the 
likelihood of inhibition within a biological context.  
Several groups have shown that Gremlin-1 binds to heparin with 20 nM binding affinity, proving that 
such Gremlin-1 interaction with the extracellular environment is important for localization of BMP 
activity gradients in tissue [42]. Tatsinkam and colleagues proposed that the heparin-binding site was 
located in three clusters of positively charges residues, mapping these onto our Grmlin-1 structure. The 
first cluster is in the C-terminus of the N-terminal -helix and the two other clusters are mapped onto the 
second finger [45,46,48]. The same position for heparin-binding site has also been reported for another 
DAN family antagonist Sclerostin [24]. Unfortunately, it has not been investigated if N-terminus in 
particular has any effect on Gremlin-1 (or other related antagonists) interaction with heparin. Given that 
the N-terminus is close to the proposed heparin-binding sites in Gremlin-1, it is possible that it does 
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contribute to heparin binding and affect the behavior of this protein in the tissue. Given that this is the 
most divergent part between DAN family members, a more detailed analysis of its role might reveal 
functional differences between these proteins.  
Biophysical analyses showed that Gremlin-1 forms a stable non-covalent dimer in solution and structure 
determination of the conserved cystine knot part of the protein revealed an arch-shaped structure,   
composed mainly of β-sheets. The structure is very similar to that of Gremlin-2, as was predicted based 
on the high sequence similarity between these proteins. Although structures of many Dan family proteins 
have been determined, it remains unclear as to how they block BMP-2 signaling. The structure of 
Gremlin-1 in complex with BMP-2 would provide considerably more insight into the binding mechanism. 
Unfortunately, crystallization trials of the BMP-2/Gremlin-1 complex were not successful. One likely 
reason for the failure to crystallize the complex lies in the heterogeneity of the sample, as illustrated by 
the complex AUC data; it was not possible to co-purify the complex. These limitations in structural 
analysis encouraged us to analyze the complex using mutagenesis of BMP-2 and by different biophysical 
analysis. 
Novel BMP-2 mutants that had either type I or type II receptor binding site residues mutated were 
generated and shown to be inactive or have significantly reduced activity in mouse myoblast bioassay. 
When these mutants were tested for their ability to interact with Gremlin-1, the binding was only partially 
disrupted by receptor site mutations, with reduced binding affinities, but none of the mutations resulted in 
total loss of binding. This suggests that there might be an alternative mechanism of BMP-2 inhibition to 
directly occluding the receptor interaction sites. Mutagenesis of Gremlin-2 (PRDC) has been similarly 
inconclusive, with no clear hot-spot being identified so far [31] .  
A significant number of studies have been performed to increase understanding of the BMP signaling 
pathway and the role of extracellular antagonists in modulation of signaling. Previous findings show that 
many antagonists function through direct inhibition of BMPs by blocking their receptor binding sites. 
Noggin undergoes ‘head-to-head’ dimerization which results in an arch shaped dimer that shields the 
concave face of the active BMP-7 dimer. Furthermore, Noggin has flexible N-terminal ‘clip’ segments 
that form hydrophobic interactions with the BMPR-I binding pocket [20]. These N-termini wrap around 
the BMP-7 dimer and are suggested to be responsible for the high affinity interaction. Crossveinless 2 
(CV-2)  binds to BMP-2 using its von Willebrand factor type C domain (VWC-1), with flexible N-
terminal ‘clips’ of the VWC-1 wrapping around BMP, blocking both type I and II receptor binding sites 
[33]. Follistatin antagonizes many TGF- ligands, including activins, Myostatin and BMPs, using a 
distinctly different mode of interaction with its ligands to achieve inhibition. All four globular domains of 
follistatin participate in ligand binding with  flexible linkers allowing a pair of follistatin molecules to 
wrap around the mature growth factor, blocking both type I and II receptor binding pockets [49,50]. 
None of the aforementioned inhibition mechanisms seem to be applicable to the Gremlin-1 and BMP-2 
interaction. The shape of  Gremlin-1 is not unlike the shape of its ligand, BMP-2, and it is difficult to 
imagine geometrically how two such curved and elongated structures, both with internal two-fold 
symmetry could bind the other dimer with 1:1 stoichiometry while  occluding  receptor binding sites 
which lie in the opposite sides of  BMP-2 dimer. Binding experiments show that both short and full length 
Gremlin-1 constructs exhibit near identical binary interactions with BMP-2 and that the flexible N-
terminal sequence does not influence ligand binding as is the case for Noggin or CV-2. Additionally, the 
arched Gremlin-1 dimer is more rigid than a multi-domain follistatin, and thus unlikely to change its 
conformation significantly upon binding to the ligand. AUC experiments showed that Gremlin-1 and 
BMP-2 form large complexes in solution  raising the idea of Gremlin-1 sequestering BMP-2 into an 
oligomeric complex and thus preventing receptor interaction and signaling. cell surface clustering of 
BMP-2 by repulsive guidance molecule (RGM) and neogenin has been suggested recently [51]. Such a 
clustering model seemed plausible for the complex of Gremlin-1 and BMP-2 as well and was tested using 
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specially designed biosensor experiments. The results of additive biolayer interferometry experiments 
showed incremental layer formation, indicating that Gremlin-1 can bind to more than one BMP-2 
molecule at a time and vice versa, resulting in an alternating oligomer of Gremlin-1 and BMP-2. The 
affinities of the first and the second BMP-2 binding events were similar, suggesting that at the molecular 
level, these events are equivalent. Higher oligomeric complexes of Gremlin-1 and BMP-2 might function 
differently depending on the concentration of Gremlin-1 and thus exert more complex regulation on the 
growth factor, beyond simply inhibiting its activity. Agonists of BMPs can facilitate endocytic uptake of 
the growth factors in dose dependent manner, but with Gremlin this process seems to be inhibited by at 
higher concentrations [18]. No explanation for this has been revealed, but it is intriguing to think that our 
model of oligomerisation could provide a clue to this differing behavior, in comparison to other types of 
BMP inhibitors.   
Taking these results together, we can envisage several possible models of Gremlin-1 and BMP-2 
association, depicted in Figure 5. A closed, 2:2 oligomeric complex of BMP-2/Gremlin-1dimers is one 
possibility, in accordance to the size of the complex seen in AUC experiments, but ‘fibril-like’ open-
ended oligomer is an equally plausible model based on the BLI data (Figure 5C and D). 
It is easy to imagine the ‘fibril-like’ architecture of the BMP-2/Gremlin-1 complex due to the 
arrangement of α-helices in these proteins. The α-helix in BMP-2 is important for interaction with 
receptors, given it forms the binding pocket and interacts with the α-helix of BMPR-I [5]. Previous 
structural studies of BMP signaling modulators have shown that α-helix binding in the type I receptor 
pocket of the BMP dimer plays an important role in inhibition. The N-terminal α-helix which is present 
both in Gremlin-1 and -2 is suggested to be flexible, and poorly defined in the structure of Gremlin-2 
[31]. The α-helix of Gremlin-1 could be placed in the BMPR-I binding pocket, causing side-to-side 
binding of BMP-2 and Gremlin-1 (Figure 5D). The convex face of Gremlin-1 would then shield the 
hydrophobic patches of the knuckle epitope of BMP-2. Interaction of the α-helix probably has an 
additional effect on Gremlin-1 and BMP-2 binding affinity, based on the findings of previous studies. 
Firstly, Dan protein was shown to be less potent than Gremlin-2 [30]. The structure of Dan is very similar 
to the Gremlins (Figure 2), but Dan lacks the aforementioned α-helix. The same applies to another Dan 
family antagonist – Sclerostin, which also lacks the α-helix. This could be the reason why Dan and 
Sclerostin are weaker antagonists, while both Gremlins form very high affinity interactions with BMPs. 
Mutations in Gremlin-2 and Dan also show that residues on the convex faces of these proteins are 
important for BMP-2 binding, supporting the proposed model of complex formation, but further studies 
are needed to evaluate these experimentally. Electron microscopy could be used to evaluate if the 
complex forms such ‘fibril-like’ structures and further crystallographic studies are also required to 
elucidate the atomic details of the BMP-2 and Dan family proteins binding mechanism. 
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X-ray diffraction data and refinement statistics for ΔN-Gremlin-1 
Data collection and processing  
Resolution / high resolution shell (Å) 41.6-1.9 / 2.1-1.9 
Rmerge 0.049 / 0.564 
Rmeas 0.058 / 0.589 
Total number of observations 160820 / 23357 
Number of unique reflections 47349 / 6881 
Mean I/δI 15.2 /2.4 
Completeness (%) 99.6 / 99.3 
Multiplicity 3.4 / 3.4 
CC(1/2) 0.999 / 0.896 
Space group C2 
Unit cell dimensions:  
a, b, c (Å) 86.8, 106.1,78.5  
α, β, γ (°) 90.0, 121.2, 90.0 
Wavelength (Å) 0.97942 
Refinement  
Resolution /high resolution shell (Å) 67.14 – 1.90 / 1.95 – 1.90 
Number of reflections 45041 /2779 
Rwork 0.179 /0. 328 
Rfree 0.208 / 0.341 




rmsd bond length(Å) 0.007 
rmsd bond angle  (°) 1.04 
rmsd planes (°) 0.007 
Ramachandran plot: favored  / allowed / outliers 434 / 12 / 0 







Mutated site Mutant Mutations 
Type I  # 1 49 F → A 
 # 2 66 L → R 
 # 3 49 F → A, 66 L → R 
Type II # 4 33 V → T, 34 A → S 
 # 5 98 V → T, 100 L → N 
 # 6 90 L→ Q, 92 L → R 
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Analysis of fl- and N-Gremlin-1 binding BMP-2 and BMP-2 mutants  
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Figure 1. Preparation and functional analysis of Gremlin-1 constructs. (A) SDS-PAGE analysis of all 
Gremlin-1 constructs after final purification:untagged ΔN-Gremlin-1, His-tagged ΔN-Gremlin-1 (lanes 2) 
andHis-tagged fl-Gremlin-1. All  samples were analysed under reducing and non-reducing conditions, as 
indicated in the figure. (B) Gremlin-1 interaction with BMP-2. Equilibrium state binding from BLI for 
ΔN-Gremlin-1 (purple squares) and fl-Gremlin-1 (pink squares) with BMP-2 data fit to steady state 
equilibrium model shown as solid lines. (C) Gremlin-1 inhibition of BMP-2 in C2C12 cells. BMP-2 
induced alkaline phosphatase activity in C2C12 cells treated with BMP-2/ΔN-Gremlin-1 (purple squares) 
and BMP-2/Gremlin-1 (pink squares), with fit to IC50 model shown as solid lines. 
Figure 2. Crystal structure of ΔN-Gremlin-1. (A) Cartoon of ΔN-Gremlin-1 dimer with different 
chains coloured in darker and lighter purple, and labeled to indicate parts and motifs discussed in the text. 
F1 and F2 indicate the fingers, W marks the wrist region and N- and C-termini are labeled with N and C, 
respectively. (B) Close-up view of the β-sheet at the dimerization interface. Only main chain is showed 
and hydrogen bonds are represented as black dashed lines (C) Dimer of ΔN-Gremlin-1, with one of the 
two protomers shown with it molecular surface onto which the interaction surface between the protomers 
is coloured (red for oxygen atoms, blue for nitrogen atoms and yellow for carbons). (D) Close-up view of 
the interfacial-helix (in transparent outline) with side chains of hydrophobic residues interacting with 
the helix from both protomers shown as sticks. (E) Detailed view of C141 and F143 residues in 
dimerization interface. 
Figure 3. Analysis of oligomeric state of ΔN-Gremlin-1 in solution. (A) MALS analysis of ΔN-
Gremlin-1 dimer. Light scattering trace is shown in solid line, while molecular mass distribution across 
the peak is shown by red dots. (B) ΔN-Gremlin-1 crystal structure shown as a ribbon and colored surface 
with ΔN-Gremlin-1 envelope and (C) fl-Gremlin-1 envelope shown in white.  
Figure 4. BLI analysis of repetitive ΔN-Gremlin-1 interaction with BMP-2. (A) Overview of the 
design of the repetitive binding experiment, with all the components show schematically as labelled in the 
figure. The curves show BLI response for each of the eight channels which differed in the concentration 
of BMP-2 in the well, as labelled at the end point of each curve. (B) Control experiment to determine 
non-specific ΔN-Gremlin-1 binding to His-tagged ΔN-Gremlin-1 or the tip surface.  
Figure 5. Model of ΔN-Gremlin-1 and BMP-2 oligomeric complex. (A) Complex model of 2:1 
stoichiometry (two Gremlin-1 dimers: one BMP-2 dimer) (B) Complex model of 2:2 stoichiometry. (C) 
Model of complex oligomerization in ‘fibril-like’ manner. (D) Elongated model of ‘fibril-like’ complex 
formation based on crystal structure analysis. All models created “manually” by orienting molecules to 
approximate locations and is hence used for illustrative purposes only and not to be seen as a precise 
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Supplementary Figure 1: A sequence alignment of the DAN family members. All sequence align-
ments are generated with CLC Sequence Viewer 7. Cysteines are shown in yellow. The N-terminal
signal peptides are not shown. Residues mentioned in the text are numbered in bold.













































Supplementary Figure 2: Biolayer interferometry (BLI) analysis of Gremlin-1 and ∆N-Gremlin-1
interaction with BMP-2. (A) Raw BLI data of ∆N-Gremlin-1 binding BMP-2 with subtracted



























Supplementary Figure 3: Analysis of ∆N-Gremlin-1 structure. (A) Electron density map with C141
and F143 residues of the dimer. (B) Aligned ∆N-Gremlin-1 dimers from one ASU. (C) B-factor of


























Supplementary Figure 4: Comparison of Gremlins, Dan and Sclerostin structures. (A) Structure
of ∆N-Gremlin-1 (PDB identiﬁcation code 5AEJ), (B) Crystal structure of Gremlin-2 (PDB iden-
tiﬁcation code 4JPH), (C) crystal structure of Dan (PDB identiﬁcation code 4X1J) and (D) NMR
structure of Sclerostin (PDB identiﬁcation code 2KD3).
















































Supplementary Figure 5: Small-angle X-ray scattering (SAXS) analysis of ∆N-Gremlin-1 and ﬂ-
Gremlin-1. (A) Guinier plot, (B) pair distance distribution function of∆N-Gremlin-1 and ﬂ-Gremlin-
1. (C) Intensity distribution of the SAXS scattering function of ﬂ-Gremlin-1 (pink) and the curves
simulated from crystal structure of ∆N-Gremlin-1 (black line). (D) Intensity distribution of the
SAXS scattering function of ∆N-Gremlin-1 (purple) and the curves simulated from crystal structure













Supplementary Figure 6: BMP-2 structure with mutated residues and bound receptors (PDB iden-
tiﬁcation code 2GOO). Type I receptor binding site mutations are shown in red, type II  in purple.
BMPR-IA ectodomain is shown in yellow and AR-II  in green. BMP-2 protomers are shown in


















































































Supplementary Figure 7: Circular dichroism spectra and dose-response eﬀect of BMP-2 mutants on
AP activity of C2C12 cells osteoblastic diﬀerentiation. (A) Circular dichroism spectra of BMP-2
mutants. (B) Proteins with mutations in type I receptor binding site compared with wild-type
BMP-2. (C) Proteins with mutations in type II receptor binding site compared with wild-type
BMP-2.
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Supplementary Figure 8: Biolayer interferometry analysis of ∆N-Gremlin-1 interaction with BMP-2




Supplementary Figure 9: Analytical ultracentrifugation (AUC) interference analysis of ∆N-Gremlin-
1, BMP-2 and BMP-2/∆N-Gremlin-1 complex.






Grem11 5' primer (ﬂ-Gremlin-1) BspHI TATTATTCATGAAAAAGAAAGGATCACAAGGTGCC
Grem13 5' primer (∆N-Gremlin-1) BspHI TATATATCATGAGTGAGGTGCTAGAGTCAAGCCAAGAG
Grem12 3' primer HindIII TATATAAGCTTAATCCAAATCGATGGATATGCAAC
Supplementary Table 2: Octet experimental setup
Assay step Time
Regeneration 3 × 5 s





Regeneration 3 × 5 s
